A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer in Combination With Pembrolizumab as First-Line Treatment

Inclusion Criteria: * Able to provide written informed consent and is willing and able to comply with all study procedures and contraception requirements * Age ≥ 18 years at the signing of ICF * At least 1 measurable lesion as defined by RECIST 1.1 * ECOG performance status of 0 or 1 * Life expectancy ≥ 12 weeks, in the opinion of the Investigator * Adequate hematologic function * Creatinine clearance ≥ 60 mL/min calculated according to the Cockroft and Gault formula * Adequate liver function * Serum albumin ≥ 3 g/dL * Serum magnesium and corrected calcium, Grade ≤ 1 alteration * Participants…